Related Experiment Videos
Postoperative nesiritide use following high-risk mitral valve replacement
John W C Entwistle1, David E McLoughlin, Kourosh Baghelai
1Department of Cardiothoracic Surgery, Drexel University College of Medicine, Hahnemann University Hospital, Philadelphia, Pennsylvania 19102, USA.
The Heart Surgery Forum
|July 21, 2004
Summary
Nesiritide effectively treats acutely decompensated chronic heart failure. It shows promise in managing postoperative heart failure exacerbations, particularly after cardiac surgery, by lowering pressures and promoting diuresis.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Acutely decompensated chronic heart failure requires effective treatment.
- Postoperative heart failure exacerbations present management challenges, especially after cardiac surgery.
Observation:
- A case study details managing cardiogenic shock post-papillary muscle rupture.
- The patient displayed signs of heart failure in the postoperative period.
Findings:
- Nesiritide therapy was initiated to reduce filling pressures and induce diuresis.
- Nesiritide demonstrated potential utility in this complex cardiac patient.
Implications:
- Nesiritide may be a valuable therapeutic option for heart failure patients undergoing cardiac surgery.
- This highlights nesiritide's role in managing severe postoperative cardiac dysfunction.